Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 19/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25187594 | 1.00 | KEAP1 (0.56) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL30371770 | 1.00 | KEAP1 (0.56) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL29274876 | 0.94 | KEAP1 (0.54) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL25555289 | 0.94 | KEAP1 (0.54) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL29274879 | 0.94 | KEAP1 (0.54) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL23930784 | 0.94 | KEAP1 (0.54) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL30256556 | 0.94 | KEAP1 (0.54) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL30258676 | 0.91 | KEAP1 (0.52) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL23930720 | 0.91 | KEAP1 (0.52) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL23930727 | 0.89 | KEAP1 (0.62) | KEAP1NFE2L2ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | KEAP1 2/4885NFE2L2 1/4885ATM 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.